1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. ICL Group Ltd
  6. News
  7. Summary
    ICL   IL0002810146

ICL GROUP LTD

(ICL)
  Report
End-of-day quote TEL AVIV STOCK EXCHANGE  -  2022-08-16
32.63 ILS   -0.79%
08/17ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products - Evogene
AQ
08/16ICL Group to Work With Evogene's Lavie Bio Unit to Develop Novel Bio-Stimulant Products
MT
08/16ICL Group Ltd and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ICL : Other Report or Announcement

06/28/2022 | 04:30pm EDT

June 28, 2022

Appeal against the Israeli District Court's decision to dismiss the Application for Certification of a

Class Action regarding Environmental Hazards to the area of Bokek Stream

Further to the Company's immediate report dated April 25, 2022 (Reference no: 2022-02-050476), regarding the Be'er Sheva District Court decision to dismiss with prejudice the application for certification of a class action (the "Application for Certification") that was filed in March 2018 against the Company's subsidiaries, Rotem Amfert Negev Ltd. and Periclase Dead Sea Ltd., requesting compensation for alleged environmental hazards in the area of the Bokek stream, the Company hereby reports that on June 27, 2022, the plaintiffs filed an appeal with the Israeli Supreme Court against the Be'er Sheva District Court's decision to dismiss the Application for Certification.

For additional information regarding the Application for Certification, see Note 18 to the Company's Consolidated Annual Financial Statements for 2021 filed on February 23, 2022 (Ref No: 2022-02- 018666).

Name of the authorized signatory on the report and name of authorized electronic reporter: Aya Landman, Adv.

Position: VP, Corporate Secretary & Global Compliance

Signature Date: June 28, 2022

PRESS CONTACT

INVESTOR RELATIONS CONTACTS

Adi Bajayo

Peggy Reilly Tharp

Scherf Communications

VP, ICL Global Investor Relations

+972-52-4454789

+1-314-983-7665

Adi@scherfcom.com

Peggy.ReillyTharp@icl-group.com

ICL Group LTD. Millennium Tower, 23 Aranha st. Tel Aviv, Israel

T +972.541234567 W www.icl-group.com

תילגנאב חווידה חסונ אוה בייחמה חסונה - תוחונ םוגרת

2022 ינויב 28

םיעגפמ ןיינעב תיגוציי הנעבות תשגהל רושיא תשקב תייחדל יזוחמה טפשמה תיב תטלחה דגנ רוערע

קקוב ןיע לחנ רוזאב םייתביבס

םע רשקב ,(2022-02-050476 :אתכמסא 'סמ) 2022 לירפאב 25 םוימ הרבחה לש ידיימה חווידל ךשמהב תשקב") תיגוציי הנעבות רושיאל השקבה לש עבש ראבב יזוחמה טפשמה תיב ידי לע ףסה לע הייחד ,םייתביבס םיעגפמ ןיגב ,מ"עב חלמה םי סאלקירפו מ"עב בגנ טרפמא םתור תבה תורבח דגנ ("רושיאה תיבל רוערע םיעבותה ושיגה ,2022 ינויב 27 םויב יכ ,חוודל תדבכתמ הרבחה ,קקוב לחנ רוזאב ,הרואכל

.רושיאה תשקב תייחדל רומאכ יזוחמה טפשמה תיב תטלחה לע ןוילעה טפשמה

הרבחה לש םידחואמה םייתנשה םייפסכה תוחודל 18 רואיב ואר ,רושיאה תשקבל עגונב ףסונ עדימל

.(2022-02-018666 אתכמסא 'סמ) 2022 ראורבפב 23 םויב ומסרופש יפכ ,2021 תנשל

ד"וע ,ןמדנל היא :תינורטקלא המיתח השרומ םשו חודה לע המיתח השרומ םש

תילבולג הפיכא תלהנמו הרבחה תריכזמ ,ל"כנמס :הדיקפת 2022 ינויב 28 :המיתחה ךיראת

םיעיקשמ ירשק - רשק ישנא

תרושקת - רשק תשא

פרא'ת-ילייר יגפ

ויא'גב ידע

תילאבולג םיעיקשמ ירשק תיל"כנמס

תרושקת ףרש

+1-7665-983-314

+972-52-4454789

Peggy.ReillyTharp@icl-group.com

Adi@scherfcom.com

ICL Group LTD. Millennium Tower, 23 Aranha st. Tel Aviv, Israel

T +972.541234567 W www.icl-group.com

Disclaimer

ICL Group Ltd. published this content on 28 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 June 2022 20:29:11 UTC.


© Publicnow 2022
All news about ICL GROUP LTD
08/17ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products..
AQ
08/16ICL Group to Work With Evogene's Lavie Bio Unit to Develop Novel Bio-Stimulant Products
MT
08/16ICL Group Ltd and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulan..
CI
08/16ADDING MULTIMEDIA ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-..
BU
08/11ICL : Other Report or Announcement
PU
08/11ICL Group Ltd Signs Binding Memorandum of Understanding with A European Customer, to Su..
CI
08/03ICL to Participate in Fireside Chat at Jefferies Industrials Conference
BU
07/28BMO Capital Adjusts Price Target on ICL Group to $11 From $12, Maintains Market Perform..
MT
07/27TRANSCRIPT : ICL Group Ltd, Q2 2022 Earnings Call, Jul 27, 2022
CI
07/27ICL : INCORPORATION BY REFERENCE - Form 6-K
PU
More news
Analyst Recommendations on ICL GROUP LTD
More recommendations
Financials (USD)
Sales 2022 10 499 M - -
Net income 2022 2 257 M - -
Net Debt 2022 1 865 M - -
P/E ratio 2022 5,74x
Yield 2022 9,10%
Capitalization 12 915 M 12 915 M -
EV / Sales 2022 1,41x
EV / Sales 2023 1,59x
Nbr of Employees 12 000
Free-Float 52,5%
Chart ICL GROUP LTD
Duration : Period :
ICL Group Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ICL GROUP LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 10,03 $
Average target price 10,52 $
Spread / Average Target 4,80%
EPS Revisions
Managers and Directors
Raviv Zoller President & Chief Executive Officer
Aviram Lahav Chief Financial Officer
Yoav Doppelt Executive Chairman
Miri Mishor Executive Vice President-Information Technology
Anantha N. Desikan Chief Research, Development & Innovation Officer
Sector and Competitors
1st jan.Capi. (M$)
ICL GROUP LTD8.73%12 915
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.107.06%29 826
PHOSAGRO35.93%16 979
UPL LIMITED5.78%7 469
YUNNAN YUNTIANHUA CO., LTD.34.76%7 158
PI INDUSTRIES LIMITED13.07%6 553